biote (BTMD) Stock Price, News & Analysis

Company Overview

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Key Stats

• Today's Range: $5.96 to $6.12
• 50-Day Range: $5.00 to $6.72
• 52-Week Range: $3.65 to $8.44
• Volume: 1,202 shs
• Average Volume: 165,077 shs
• Market Capitalization: $323.15 million
• P/E Ratio: 22.92
• Dividend Yield: N/A
• Price Target: $8.39
• Consensus Rating: Buy

biote Stock Analysis - MarketRank™

biote scored higher than 64% of companies evaluated by MarketBeat, and ranked 405th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

biote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

biote has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -27.63%

Earnings Growth

Earnings for biote are expected to decrease by -27.63% in the coming year, from $0.76 to $0.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of biote is 23.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of biote is 23.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.86.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.70% of the float of biote has been sold short.

Short Interest Ratio / Days to Cover

biote has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in biote has recently decreased by 8.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

biote does not currently pay a dividend.

Dividend Growth

biote does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.70% of the float of biote has been sold short.

Short Interest Ratio / Days to Cover

biote has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in biote has recently decreased by 8.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

biote has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for biote this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, biote insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.68% of the stock of biote is held by institutions.

BTMD Stock Analysis - Frequently Asked Questions

How have BTMD shares performed this year?

biote's stock was trading at $4.94 at the beginning of the year. Since then, BTMD shares have increased by 22.7% and is now trading at $6.06.
View the best growth stocks for 2024 here.

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) released its earnings results on Thursday, August, 10th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.34. The business earned $49.26 million during the quarter, compared to analyst estimates of $46.76 million. biote had a net margin of 5.20% and a negative trailing twelve-month return on equity of 32.41%.

Who are biote's major shareholders?

Top institutional investors of biote include Wasatch Advisors LP (2.57%), Geode Capital Management LLC (1.03%), State Street Corp (0.88%) and Jacobs Levy Equity Management Inc. (0.50%). Insiders that own company stock include Roystone Capital Management Lp, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar.
View institutional ownership trends.

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of biote own?

Based on aggregate information from My MarketBeat watchlists, some other companies that biote investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BTMD
• CUSIP: N/A
• CIK: 1819253
• Web: biote.com
• Phone: 844-604-1246
• Fax: 212-616-9601
• Employees: 194
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.39
• High Stock Price Target: $9.00
• Low Stock Price Target: $6.55
• Potential Upside/Downside: +38.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.26
• Trailing P/E Ratio: 23.31
• Forward P/E Ratio: 7.97
• P/E Growth: N/A
• Net Income: $3.32 million
• Net Margins: 5.20%
• Pretax Margin: 5.99%
• Return on Equity: -32.41%
• Return on Assets: 22.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $193.06 million
• Price / Sales: 1.70
• Cash Flow: $0.56 per share
• Price / Cash Flow: 10.83
• Book Value: ($0.58) per share
• Price / Book: -10.45

Miscellaneous

• Outstanding Shares: 54,218,000
• Free Float: 46,682,000
• Market Cap: $328.56 million
• Optionable: Not Optionable
• Beta: 0.94